Ligand Pharmaceuticals Incorporated Forecast, price target & analysts
Ligand Pharmaceuticals Incorporated Target price 2026 - Analyst rating & recommendation
Ligand Pharmaceuticals Incorporated Classifications & Recommendation
Ligand Pharmaceuticals Incorporated Price Target
| Target Price | $351.90 |
| Price | $302.96 |
| Potential |
16.15%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Ligand Pharmaceuticals Incorporated 2027 .
The average Ligand Pharmaceuticals Incorporated target price is $351.90.
This is
16.15%
register free of charge
$409.50
35.17%
register free of charge
$249.47
17.66%
register free of charge
|
|
| A rating was issued by 16 analysts: 15 Analysts recommend Ligand Pharmaceuticals Incorporated to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ligand Pharmaceuticals Incorporated stock has an average upside potential 2027 of
16.15%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 215.02 | 295.62 |
| 28.65% | 37.48% | |
| EBITDA Margin | 14.62% | 65.77% |
| 56.35% | 349.80% | |
| Net Margin | 57.88% | 63.66% |
| 2,500.30% | 9.99% |
13 Analysts have issued a sales forecast Ligand Pharmaceuticals Incorporated 2026 . The average Ligand Pharmaceuticals Incorporated sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Ligand Pharmaceuticals Incorporated EBITDA forecast 2026. The average Ligand Pharmaceuticals Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Ligand Pharmaceuticals Incorporated Analysts have issued a net profit forecast 2026. The average Ligand Pharmaceuticals Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 6.13 | 9.45 |
| 2,886.36% | 54.16% | |
| P/E | 32.07 | |
| EV/Sales | 19.65 |
13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast for earnings per share. The average Ligand Pharmaceuticals Incorporated EPS is
This results in the following potential growth metrics and future valuations:
Ligand Pharmaceuticals Incorporated...
Current Ligand Pharmaceuticals Incorporated Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Sep 25 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 24 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 03 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 25 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 24 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 03 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
